Tumor-reactive γδ T Cells Mediate Responses to the Antibody Drug Conjugate Belantamab Mafodotin in Multiple Myeloma
Presented September 2025 at International Myeloma Society Congress
Isatuximab Cyclophosphamide Bortezomib and Dexamethasone Induction and Autologous Stem Cell Transplant in Newly Diagnosed Myeloma: Report of the Prospective Canadian Myeloma Research Group 008 Trial
Presented: June 2024, European Haematology Association Congress
Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial
Presented: December 2023 American Society of Hematology (ASH) Congress
A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard Cybord Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma
Presented: December 2021 American Society of Hematology (ASH) Congress
Extended Follow-Up Safety and Efficacy Results of Belantamab Mafodotin (Belamaf) 1.92 Mg/Kg Or 2.5 Mg/Kg Combined with Pom and Dex for the Treatment of Relapsed/Refractory Multiple Myeloma
Presented September 2021 at International Myeloma Society Congress
Outcomes Of Daratumumab-Containing Regimens in The Treatment of Relapsed Multiple Myeloma: Real-World Data from The Canadian Myeloma Research Group Database
Presented June 2021 at European Hematology Association Congress
Survival And Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status Diagnosed Between 2007-2018: Real-World Analysis from the Canadian Myeloma Research Group Database
Presented June 2021 at European Hematology Association Congress
Carfilzomib-Containing Regimens For Relapsed Multiple Myeloma In A Real-World Setting: A Multi-Institutional Report From The Canadian Myeloma Research Group (CMRG)
Presented June 2021 at European Hematology Association Congress
Maintenance Therapy but Not Tandem Autologous Stem Cell Transplant (ASCT) Improves outcomes in Multiple Myeloma with High-Risk Cytogenetics: Results from The Canadian Myeloma Research Group (CMRG) Database
Presented December 2020 American Society of Hematology (ASH) Congress
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
Presented December 2020 American Society of Hematology (ASH) Congress
Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database
Presented December 2020 American Society of Hematology (ASH) Congress
Part 1 Results of a Dose Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Presented December 2020 American Society of Hematology (ASH) Congress
A Phase 2 Study of Belantamab Mafodotin (GSK2857916) in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM): Results for Part 1 Dose Finding
Presented June 2020 at European Hematology Association Congress
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma
Presented December 2019 American Society of Hematology (ASH)
Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens
Presented December 2019 American Society of Hematology (ASH)
The ALGONQUIN Study: A Phase 1/2 Multi-Center, Dose Escalation Study to Determine the RP2D, Safety and Efficacy of GSK2857916 in Combination with Pomalidomide and Low Dose Dexamethasone in Subjects with RRMM
Presented September 2019 at International Myeloma Society Congress
Initial Results of MCRN 009: Phase 2 Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (MM)
Presented September 2019 at International Myeloma Society Congress
The Impact of Lenalidomide Maintenance on Second Line Chemotherapy in Transplant Eligible Patients with Multiple Myeloma in the Canadian Setting
Presented September 2019 at International Myeloma Society Congress
Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database
Presented December 2018 American Society of Hematology (ASH)
CMRG 003/MYX·1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies
Presented December 2018 American Society of Hematology (ASH)
The Myeloma Canada Research Network Canadian Multiple Myeloma Database (MCRN CMMDB): Multi-Institutional Sharing of Clinical Data for Research
Presented June 2018 at European Hematology Association Congress
Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments
Presented December 2016 American Society of Hematology (ASH)
Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial
Presented December 2016 American Society of Hematology (ASH)
Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum HevyliteTMÂ chain (HLC) Normalization
Published December 2015 at American Society of Hematology
Myeloma Canada Research Network (MCRN) 001 Trial with Intravenous (IV) Busulfan + Melphalan (BuMel) as Enhanced Conditioning, followed by Lenalidomide (Len) Maintenance in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts): First Results of Minimal Residual Disease (MRD) and Hevylite(TM) Chain (HLC) Assays at Day 100 Post Autologous Stem Cell Transplant (ASCT)
Published September 2015 at International Myeloma Workshop
First Report of the Myeloma Canada Research Network -001 Trial Utilizing Bortezomib-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide Maintenance
Published December 2014 at American Society of Hematology